Suppression of T-cell responses by host-derived regulatory factors is
C
learance of viral infections is dependent on functional T-cell responses. However, following some viral infections, T cells rapidly lose their ability to proliferate, to lyse virally infected cells, and to produce multiple effector molecules (1) (2) (3) (4) . The loss of these polyfunctional T-cell responses (termed ''exhaustion'') directly leads to the failure to eliminate the virus and terminate the infection. Sustained T-cell activity prevents persistent viral infection. Prolonged T-cell responses strongly correlate with acute clearance of hepatitis C virus (HCV) infection and transfer of functional virus-specific CD4 and CD8 T cells completely eliminates an established persistent viral infection (5) (6) (7) (8) (9) (10) . In addition to viral components (11) , the host-derived suppressive cytokine IL-10 and the programmed death-1 (PD-1)/PD-ligand (L) 1 inhibitory pathways actively suppress T-cell responses, allowing viral persistence (9, 12, 13) . Antibody blockade to relieve IL-10 or PD-L1-mediated inhibition in vivo rapidly enhances T-cell function and reduces viral replication (9, 12, 13) . Thus, the re-establishment of functional T-cell responses leads to increased control of persistent viral infection, but in many cases an even further enhancement of immunity is required to completely eliminate infection (5, 9, (12) (13) (14) .
The suppressive environment maintained by IL-10 and PD-L1 not only limits T-cell responses to infection, but also inhibits the ability to stimulate immunity through vaccination (15, 16 ). Yet, despite the profound impact IL-10 and PD-L1 have on T-cell immunity, little is known about the actual mechanisms used to suppress the immune response. Consequently, whether these suppressive factors induce each other and function through a linear pathway or whether they are invoked and function through distinct mechanisms is unclear. Defining these mechanisms of suppression is necessary to determine whether simultaneous blockade of IL-10 and PD-L1 will further enhance T-cell immunity and more effectively control persistent viral replication. Here, we demonstrate that IL-10 and PD-L1 suppress antiviral T-cell activity via separate pathways and consequently, simultaneous blockade of IL-10 and PD-L1 dramatically increases T-cell responses over that seen by neutralizing either molecule alone. The combinatorial blockade of both IL-10 and PD-L1 rapidly eliminates persistent virus infection.
Results

Distinct Mechanisms of IL-10 and PD-1/PD-L1 Immunosuppression During
Persistent Viral Infection. To determine the functional relationship between IL-10 and the PD-1/PD-L1 pathways during persistent viral infection, WT C57BL/6 mice or C57BL/6 mice genetically deficient in IL-10 (IL-10 KO) or PD-L1 (PD-L1 KO) were infected with lymphocytic choriomeningitis virus (LCMV) Clone 13 (Cl 13). Infection with LCMV-Cl 13 generates a persistent infection that rapidly aborts T-cell function by inducing the expression of host-immunosuppressive factors (9, 12, 13) . To evaluate if the increased expression of IL-10 triggered the up-regulation of PD-1 on virus-specific CD8 T cells or PD-L1 on antigen-presenting cells (APC) (i.e., dendritic cells, B cells, macrophages), WT C57BL/6 and IL-10-deficient mice were infected with LCMV. Because IL-10-deficient mice rapidly clear the otherwise persistent LCMV-Cl 13 infection, PD-1/PD-L1 levels were analyzed 5 days after LCMV-Cl 13 infection at a time when T-cell responses and viral titers are similarly high in WT mice and IL-10-deficient mice (serum viral titers in WT: 2.5 ϫ 10 4 Ϯ 2.2 ϫ 10 4 versus IL-10 KO: 7.1 ϫ 10 3 Ϯ 4.9 ϫ 10 3 ; n ϭ four mice per group; P ϭ 0.22). The similar virus titers enable differentiation of factors induced by IL-10 versus those triggered in response to heightened virus replication despite the acute clearance of LCMV-Cl 13 in IL-10 KO mice (9, 13) . Five days after infection, PD-1 expression was similar on virus-specific CD8 T cells in WT and IL-10-deficient mice ( Fig. 1 A) , indicating that IL-10 is not required for the up-regulation of PD-1 on T cells during viral infection.
In addition to increased PD-1 on T cells, expression of its ligand PD-L1 is an important determinant of immunosuppression (12) . To determine whether the IL-10 produced in response to infection induces PD-L1 up-regulation, we assessed PD-L1 expression on multiple APC subsets during LCMV-Cl 13 infection. In the absence of IL-10, PD-L1 expression was modestly elevated on dendritic cells (DCs) (Fig. 1B) and expressed similarly by B cells and macrophages compared to WT mice (see Fig. 1 B and C) , suggesting a slight potential compensation by one immune-regulatory pathway in the absence of another. Although PD-L1 is the dominant suppressive ligand for PD-1 during persistent infection, we additionally measured expression of the second PD-1 ligand, PD-L2. PD-L2 expres-sion was minimal by APC, but was nonetheless expressed at the same level in WT mice and IL-10-deficient mice (see Fig. 1 B and C), indicating that PD-L1 and PD-L2 expression are not initially increased because of the high levels of IL-10 following infection.
PD-1/PD-L1 signaling may instead trigger increased IL-10 expression to suppress T-cell immunity. To test the contribution of PD-L1 signaling on IL-10 induction, IL-10 RNA expression was quantified in PD-L1 KO mice. Similar to IL-10-deficient mice, on day 5 after LCMV-Cl 13 infection virus titers are similar in PD-L1 KO mice and WT mice (serum viral titers in WT: 2.5 ϫ 10 4 Ϯ 2.2 ϫ 10 4 versus PD-L1 KO: 6.3 ϫ 10 3 Ϯ 3 ϫ 10 3 ; n ϭ four mice per group; P ϭ 0.23). The absence of PD-L1 signaling did not significantly alter IL-10 expression in the spleen (Fig. 1D) . Thus, in response to infection with a persistent virus, IL-10 and PD-1/PD-L1 represent separate pathways of immunosuppression.
Dual IL-10R/PD-L1 Blockade Further Enhances Polyfunctional T-Cell
Activity. The distinct pathways of IL-10 and PD-1/PD-L1 during persistent viral infection suggest that inhibition of both suppressive factors could substantially boost T-cell immunity. To determine whether IL-10R and PD-L1 coblockade further enhances antiviral T-cell activity compared to either treatment alone, WT mice were depleted of CD4 T-cells and infected with LCMV-Cl 13 to generate a persistent infection. Beginning on day 49 after infection, blockingantibody treatment was initiated. Mice were treated with either (i) isotype control antibody, (ii) IL-10R-blocking treatment antibody alone, (iii) PD-L1-blocking treatment alone, or (iv) dual therapy with both IL-10R and PD-L1-blocking antibodies. Mice received antibody every 3 days for a total of five treatments (i.e., spanning a period of 12 days). Antiviral T-cell responses were then quantified 3 days after the completion of therapy. Compared with isotype, individual treatment with either anti-IL-10R or anti-PD-L1-blocking antibodies significantly elevated the frequency and number of tetramer-positive (virus-specific) CD8 T cells in lymphoid (spleen) and nonlymphoid (liver and lung) tissues ( Fig. 2 A and B) . Even more impressive, the simultaneous administration of IL-10R and PD-L1-blocking antibodies further increased the frequency and the absolute number of tetramerϩ, virus-specific CD8 T cells in multiple tissue compartments and against both dominant (GP [33] [34] [35] [36] [37] [38] [39] [40] [41] ) and subdominant (GP 276 -286 ) LCMV epitopes (see Fig. 2 A and  B) . Furthermore, dual blockade increased the frequency of actively proliferating Ki67ϩ virus-specific CD8 T cells when compared to isotype control or either antibody treatment alone (Fig. 2C) , suggesting that the increased number of virus-specific CD8 T cells following IL-10 or PD-L1 blockade is because of enhanced proliferation.
In addition to increasing the total number of virus-specific cells, dual blockade also increased T-cell function. When administered in combination, IL-10R/PD-L1 coblockade increased the frequency of IFN␥-producing CD8 T cells compared to either treatment alone or with isotype control antibody (Fig. 2D ). Importantly, dual blockade elevated the frequency of polyfunctional CD8 T cells able to simultaneously produce both IFN␥ and TNF␣ (Fig. 2E ). In these studies, CD4 T cells were depleted before infection to enhance the magnitude of CD8 T-cell exhaustion and provide a situation wherein persistent Cl 13 infection is never resolved and is maintained for life (17, 18) . This enabled analyses of the ability of each treatment to restore T-cell function in a harsher immune environment (i.e., prolonged and elevated viral replication) and after extended periods of exhaustion that not achievable in non-CD4-depleted mice (12) . However, similar results were observed in non-CD4-depleted mice when antibody treatments were initiated on day 25 after infection (data not shown). Thus, combination blockade of IL-10 and PD-L1 activity effectively increased the amount and functionality of virus-specific CD8 T cells during persistent infection.
IL-10/PD-L1 Coblockade Restores Function to Previously Exhausted
T-Cells. Although functional antiviral T-cell responses are clearly elevated by dual IL-10R/PD-L1 blockade, whether activity is being resurrected from previously exhausted T-cells or de novo activation of new thymic emigrants is unclear. To address this issue, naive Thy1.1ϩ TcR tg LCMV-GP 33-41 -specific CD8 T-cells were adoptively transferred into Thy1.2ϩ C57BL/6 mice before infection. Two days following cell transfer, the mice were subsequently infected with LCMV-Cl 13 and treated with single or dual antibody therapy, beginning on day 25 after infection. The cotransfer enabled analysis of LCMVspecific T cells that were present from the beginning of infection and that subsequently became exhausted during viral persistence. Importantly, the transgenic LCMV-specific CD8 T cells could be distinguished from endogenous (i.e., hostderived) antiviral T cells based on Thy1.1 versus Thy1.2 expression, excluding analysis of new thymic emigrants. Similar to their endogenous counterparts (see Fig. 2 ), dual IL-10R/PD-L1 blockade further increased the frequency and number of previously exhausted virus-specific T cells (Fig. 3A) . All antibody blockade treatments substantially increased the frequency of IFN␥/TNF␣-producing cells compared to isotype antibody treatment, although similar increases in the percentage of IFN␥/TNF␣-producing cells was observed following IL-10R and PD-L1 blockade alone or in combination (Fig. 3B) . However, combined with the increase in the number of virus-specific T cells following dual IL-10R/PD-L1 blockade, there was a dramatic increase in the absolute number of polyfunctional, IFN␥/TNF␣-producing cells by over 12-fold, compared to isotype treatment, and over 2.5-to 6-fold compared with PD-L1 or IL-10R treatment alone, respectively (see 
Elimination of Persistent Viral Infection by Dual IL-10R/PD-L1 Block-
ade. Based on the critical role functional T cells play in controlling persistent viral infection (5), we next determined if the heightened T-cell responses induced by dual IL-10R/PD-L1 blockade also led to an enhanced ability to control persistent virus replication. Before treatment, serum virus titers were similar in all groups (Fig. 4A) . Following the 2-week therapeutic regimen, individual IL-10R or PD-L1 therapies each led to a 21-fold and 19-fold reduction, respectively, in virus titers compared to isotype treatment (see Fig.  4A ). Even more impressive, coadministration of IL-10R and PD-L1 blockade induced a highly significant 130-fold decrease in serum virus titers, with the majority of mice having undetectable levels of viral replication (see Fig. 4A ). Similarly, with the exception of one mouse that did not respond to anti-IL-10R treatment alone, viral titers were reduced by over two to three logs in the livers of antibody-treated animals compared to isotype control treatment (Fig. 4B) , indicating systemic control of virus replication. Thus, dual IL-10R/PD-L1 blockade enables rapid and enhanced control of persistent infection.
Discussion
Understanding the complex mechanisms that regulate T-cell immunity is crucial for the design of T-cell regenerative therapies to purge an established persistent viral infection. Herein, we make the discovery that two of the dominant factors that suppress antiviral immunity during viral persistence operate through distinct pathways to restrain T-cell activity. Interestingly, in IL-10-deficient mice, PD-L1 expression was increased on DCs, suggesting that in the absence of one regulatory network the immune system may compensate by increasing the expression of other regulatory factors to suppress errant immune responses and autoimmunity. Alternatively, in the absence of IL-10, the elevated level of immune activation (i.e., type I and type II interferons) following LCMV-Cl 13 infection may enhance PD-L1 on DCs (19) . The precise factors that differentially regulate IL-10 and PD-L1 expression are under investigation. However, as a result of using different pathways, combination therapy that neutralized both of these immunosuppressive pathways dramatically restored and boosted antiviral T-cell activity to control an established, persistent viral infection as compared to blockade of either pathway alone.
Virus-specific T cells proliferate and simultaneously produce multiple effector molecules in response to viral infection. The ability of T cells to simultaneously possess multiple antiviral effector functions is an indicator of the efficacy of the immune response and the loss of these polyfunctional T cells is a key event on the path to viral persistence (3, 9, 13, 20) . The level of polyfunctionality in the virus-specific T-cell repertoire is correlated with acute clearance of HCV infection and enhanced control of HIV replication (21) (22) (23) (24) , suggesting that therapeutic strategies that restore polyfuntionality to T cells may be more effective in fighting viral infection. One of the most striking impacts of dual IL-10R/PD-L1 blockade is the IFNγ   100  101  102  103  104   100   101   102   103   104   100  101  102  103  104   100   101   102   103   104   100  101  102  103  104  100  101  102  103  104  100  101  102  103  104   100   101   102   103   104   100   101   102   103   104   100   101   102   103   104   2.2%   Isotype   100  101  102  103  104   100   101   102   103   104   100  101  102  103  104   100   101   102   103   104   100  101  102  103  104  100  101  102  103  104  100  101  102  103  104   100   101   102   103   104   100   101   102   103   104   100   101   102   103   104 5.5% 100  101  102  103  104   100   101   102   103   104   100  101  102  103  104   100   101   102   103   104   100  101  102  103  104  100  101  102  103  104  100  101  102  103  104   100   101   102   103   104   100   101   102   103   104   100   101   102   103   104 6.3% 100  101  102  103  104   100   101   102   103   104   100  101  102  103  104   100   101   102   103   104   100  101  102  103  104  100  101  102  103  104  100  101  102  103  104   100   101   102   103   104   100   101   102   103   104   100   101   102   103   104   10% αIL-10R + αPD-L1 enhanced frequency and particularly the increased number of polyfunctional virus-specific T cells able to proliferate and produce multiple effector cytokines in response to viral antigen. It is interesting that the ultimate increase in the number of virus-specific CD8 T cells following IL-10R and PD-L1 blockade alone or in combination was consistent with the level of proliferation induced by each treatment (i.e., Ki67 staining) (see Fig. 3 ). On the other hand, IL-10R and/or PD-L1 blockade only modestly increased the frequency of TNF␣-producing cells within the total virus-specific CD8 T-cell population (i.e., IFN␥-producing cells), suggesting that the IL-10 and PD-L1 regulatory pathways function primarily by inhibiting T-cell proliferation to antigen stimulation. By alleviating IL-10 and PD-L1-mediated immunosuppression, T cells are able to proliferate, thereby increasing the size of the polyfunctional virusspecific T-cell population. Thus, the dual blockade allowed the rapid re-establishment of a large antiviral effector population, well equipped to fight and control infection. It is particularly impressive that following only 2 weeks of the dual blockade therapy (i.e., from the initiation to the completion of therapy), previously exhausted T-cells expanded and regained a level of functional activity capable of in many cases decreasing viral replication to undetectable levels. Thus, restoring T-cell immunity can occur rapidly and effectively once the dominant suppressive factors are identified and then neutralized.
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The rapid restoration of T-cell function following dual IL-10R/ PD-L1 blockade suggests that the antiviral immune response is constantly maintained on a fine line between exhaustion and productive immunity. Neutralization of a single factor restores T-cell function to control virus replication to some degree, but the entire potential of the T-cell response is still being restrained. Because multiple distinct immunoregulatory pathways are implemented to suppress T-cell activity, therapies that target different suppressive factors can be combined to further unleash T-cell responses. Importantly, the resulting increase in T-cell functionality induces a potentially greater ability to control and eliminate virus replication. One concern that arises by inhibiting these dominant immunoregulatory pathways is that they may also unleash undesired T-cell responses and autoimmunity. These pathways are instituted to prevent tissue destruction by self-reactive T cells that may have escaped thymic deletion, and mice lacking IL-10 or PD-1 can develop various forms of autoimmune disease (25) (26) (27) . Blocking the negative regulation implemented by IL-10 and PD-L1 restores antiviral immunity to control persistent virus replication, but the suppression of self-reactive T cells may also be alleviated. In our studies, no overt signs of autoimmunity were observed following IL-10R or PD-L1 blockade, likely because of the short duration of treatment, and treated mice lived normal life-spans. Thus, future strategies to treat established, persistent viral infections by blocking the negative immune-regulatory pathways need to weigh the potential acceptable risk with the benefit to controlling viral replication.
Because IL-10 and PD-L1 are increased during many persistent viral infections, our data suggest that future therapies incorporating blockade of multiple suppressive factors may rapidly reconstitute immunity and control persistent viral infections. An exciting application for immunomodulatory therapies is chronic HCV infection, in which both IL-10 and PD-1 levels are increased, clearance relies on robust antiviral T-cell activity, and no known latent reservoir for the virus exists (28) . Indeed, in vitro blockade of either IL-10 or PD-L1 increased HCV-specific T-cell responses (29) (30) (31) , suggesting that these therapies may effectively restore and amplify antiviral T-cell activity to a level sufficient to purge infection. Even in situations such as HIV, CMV, and EBV, where a long-lived, latent reservoir does exist and IL-10/PD-1 levels are elevated (28), a similar therapeutic approach targeting multiple host-derived regulatory factors could restore and sustain T-cell activity, in effect generating a large effector T-cell population and prolonged control of viral replication. Because these therapies do not directly target a specific pathogen, they are amenable to fight multiple persistent infections and would be less susceptible to virus mutation, escape, and selection, a problem for therapies that directly target viral gene products.
Our finding that immunosuppressive factors function through multiple pathways suggests that they may also function distinctly on different cell types (i.e., CD4 versus CD8 T cells, B cells, DCs, and so forth) to comprise the whole of immunosuppression. PD-L1 is likely directly targeting virus-specific T cells to inhibit their function and prevent viral clearance (32) . IL-10 is produced primarily by DCs and B cells following persistent LCMV infection (9) ; however the precise cell type (i.e., T cell, DC, B cell) that is being targeted and how IL-10 is altering this cell's function to suppress T-cell activity is unclear. Determining how different immune subsets are suppressed by IL-10 and PD-L1 during persistent viral infection is currently being explored, and will be important for the design of effective vaccine/adjuvant combinations to specifically restore antiviral T-cell function. Through these approaches, it may ultimately be possible to devise targeted-vaccine strategies to restore T-cell immunity and purge established persistent viral infections in humans. 
